Dr. Iman Imanirad, MD

Dr. Imanirad practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Imanirad's NPI, 1790872653, was assigned on October 10, 2006. Dr. Imanirad graduated from Saba University School of Medicine in 2006. Dr. Imanirad holds Florida license ME112472.

Dr. Imanirad's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Dr. Imanirad's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Imanirad to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Imanirad practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Imanirad's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Imanirad is board certified in hematology by the American Board of Internal Medicine. Dr. Imanirad is licensed in Florida.

Dmand AI lists colorectal cancer, lung cancer, multiple myeloma and prostate cancer among the conditions Dr. Imanirad treats.

CMS data shows 447 Medicare services from Dr. Imanirad across 5 procedure codes in 2024, for 174 Medicare patients. Medicare paid $33,643 for them.

CMS counts 174 Medicare patients who saw Dr. Imanirad in 2024. The largest group is 65 to 74, with 95 patients. 75% of them have cancer, and 74% have high cholesterol. Their average risk score is 2.64, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Imanirad's median patient age at 63, with 54% women.

In 2024, Dr. Imanirad wrote 448 Medicare Part D claims for 107 patients. 84% of them were for generic drugs. CMS names the drug for 277 of them, across 10 drugs with 11 or more claims each, at $336,895 in total drug cost. In 2023, CMS named 217 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Imanirad for performance year 2024, reported as part of a group. Dr. Imanirad accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Imanirad as offering telehealth.

Dmand AI links 39 papers to Dr. Imanirad, published from 2011 to 2025. 2021 was the busiest year, with 8. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Rectal Neoplasms and Colorectal Neoplasms. Dr. Imanirad has published most often in Cancers (Basel). Dr. Imanirad's most frequent co-authors are Seth Ian Felder, MD, Sophie Dessureault, MD, PhD and Jessica M. Frakes.

Dmand AI links Dr. Imanirad to 4 clinical trials, 3 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Colonic Neoplasms, Rectal Neoplasms and Stomach Neoplasms. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 2.

CMS Open Payments shows 139 general payments to Dr. Imanirad from 26 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 67% of the total. Incyte Corporation paid the most, $8,358.

Dr. Imanirad graduated from Saba University School of Medicine in 2006.

Dr. Imanirad is in network with 9 carriers, including Excellus BlueCross BlueShield, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.